Results 151 to 160 of about 47,865 (277)
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang +3 more
wiley +1 more source
ABSTRACT Background The clinical focus of haemophilia has expanded beyond bleeding outcomes to encompass long‐term comorbidities such as cardiovascular disease (CVD). However, it remains unclear when vascular changes begin in this population. Carotid intima‐media thickness (cIMT), a validated, non‐invasive marker of subclinical atherosclerosis, may ...
Alyson Trillo +5 more
wiley +1 more source
Localization of surface vWF on resting and stimulated platelets [PDF]
JH Rand, RE Gordon, RR Uson, BJ Potter
openalex +1 more source
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova +2 more
wiley +1 more source

